Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

  • A C Antoniou
  • P D P Pharoah
  • S Narod
  • H A Risch
  • J E Eyfjord
  • J L Hopper
  • Håkan Olsson
  • O Johannsson
  • Åke Borg
  • B Pasini
  • P Radice
  • S Manoukian
  • D M Eccles
  • N Tang
  • E Olah
  • H Anton-Culver
  • E Warner
  • J Lubinski
  • J Gronwald
  • B Gorski
  • H Tulinius
  • S Thorlacius
  • H Eerola
  • H Nevanlinna
  • K Syrjakoski
  • O P Kallioniemi
  • D Thompson
  • C Evans
  • J Peto
  • F Lalloo
  • D G Evans
  • D F Easton
Publishing year: 2005
Language: English
Pages: 602-603
Publication/Series: Journal of Medical Genetics
Volume: 42
Issue: 7
Document type: Journal article
Publisher: BMJ Publishing Group

Abstract english

A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.


  • Medical Genetics


  • ISSN: 0022-2593
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2